Latest Insider Transactions at Apellis Pharmaceuticals, Inc. (APLS)
This section provides a real-time view of insider transactions for Apellis Pharmaceuticals, Inc. (APLS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Apellis Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Apellis Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 29
2025
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
695
-0.48%
|
$20,155
$29.52 P/Share
|
|
Jan 29
2025
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
546
-0.42%
|
$15,834
$29.52 P/Share
|
|
Jan 29
2025
|
Adam J. Townsend Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
695
-0.82%
|
$20,155
$29.52 P/Share
|
|
Jan 29
2025
|
Jeffrey Eisele Chief Development Officer |
SELL
Open market or private sale
|
Direct |
278
-0.5%
|
$8,062
$29.52 P/Share
|
|
Jan 29
2025
|
Karen Lewis Chief People Officer |
SELL
Open market or private sale
|
Direct |
364
-0.52%
|
$10,556
$29.52 P/Share
|
|
Jan 29
2025
|
Nur Nicholson Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
825
-0.98%
|
$23,925
$29.52 P/Share
|
|
Jan 29
2025
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
826
-0.07%
|
$23,954
$29.52 P/Share
|
|
Jan 29
2025
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
365
-0.43%
|
$10,585
$29.52 P/Share
|
|
Jan 29
2025
|
Cedric Francois Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,824
-0.67%
|
$81,896
$29.52 P/Share
|
|
Jan 22
2025
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
3,323
-2.24%
|
$99,690
$30.43 P/Share
|
|
Jan 22
2025
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,088
-2.33%
|
$92,640
$30.43 P/Share
|
|
Jan 22
2025
|
Adam J. Townsend Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,323
-3.77%
|
$99,690
$30.43 P/Share
|
|
Jan 22
2025
|
Nur Nicholson Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
3,948
-4.46%
|
$118,440
$30.43 P/Share
|
|
Jan 22
2025
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,948
-0.34%
|
$118,440
$30.43 P/Share
|
|
Jan 22
2025
|
Jeffrey Eisele Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,291
-2.27%
|
$38,730
$30.43 P/Share
|
|
Jan 22
2025
|
Cedric Francois Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
13,551
-3.14%
|
$406,530
$30.43 P/Share
|
|
Jan 22
2025
|
Karen Lewis Chief People Officer |
SELL
Open market or private sale
|
Direct |
1,751
-2.42%
|
$52,530
$30.43 P/Share
|
|
Jan 22
2025
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
1,396
-1.62%
|
$41,880
$30.43 P/Share
|
|
Jan 22
2025
|
James George Chopas VP/Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,096
-2.23%
|
$32,880
$30.43 P/Share
|
|
Jan 21
2025
|
Timothy Eugene Sullivan Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,929
+25.77%
|
-
|
|
Jan 21
2025
|
David O. Watson General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
42,762
+22.38%
|
-
|
|
Jan 21
2025
|
Karen Lewis Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,508
+28.26%
|
-
|
|
Jan 21
2025
|
Nur Nicholson Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,426
+29.17%
|
-
|
|
Jan 21
2025
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,045
+1.29%
|
-
|
|
Jan 21
2025
|
Cedric Francois Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
130,662
+23.22%
|
-
|
|
Jan 21
2025
|
Caroline Baumal Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
39,594
+29.79%
|
-
|
|
Jan 21
2025
|
James George Chopas VP/Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,591
+20.37%
|
-
|
|
Jan 21
2025
|
Mark Jeffrey De Long Chief Business & Strat Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,508
+24.88%
|
-
|
|
Jan 17
2025
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,730
-1.96%
|
$50,170
$29.96 P/Share
|
|
Jan 17
2025
|
Adam J. Townsend Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,201
-2.44%
|
$63,829
$29.96 P/Share
|
|
Jan 17
2025
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
2,201
-2.04%
|
$63,829
$29.96 P/Share
|
|
Jan 17
2025
|
Karen Lewis Chief People Officer |
SELL
Open market or private sale
|
Direct |
1,241
-2.75%
|
$35,989
$29.96 P/Share
|
|
Jan 17
2025
|
Nur Nicholson Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
2,145
-3.96%
|
$62,205
$29.96 P/Share
|
|
Jan 17
2025
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
750
-0.07%
|
$21,750
$29.96 P/Share
|
|
Jan 17
2025
|
Cedric Francois Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
6,007
-1.95%
|
$174,203
$29.96 P/Share
|
|
Jan 17
2025
|
Caroline Baumal Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,853
-3.34%
|
$53,737
$29.96 P/Share
|
|
Jan 17
2025
|
James George Chopas VP/Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
715
-1.91%
|
$20,735
$29.96 P/Share
|
|
Jan 17
2025
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
1,235
-2.1%
|
$35,815
$29.96 P/Share
|
|
Jan 13
2025
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
4,965
-4.4%
|
$139,020
$28.7 P/Share
|
|
Jan 13
2025
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,170
-2.4%
|
$60,760
$28.7 P/Share
|
|
Jan 13
2025
|
Adam J. Townsend Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,685
-2.89%
|
$75,180
$28.7 P/Share
|
|
Jan 13
2025
|
Karen Lewis Chief People Officer |
SELL
Open market or private sale
|
Direct |
1,599
-3.42%
|
$44,772
$28.7 P/Share
|
|
Jan 13
2025
|
Nur Nicholson Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
2,632
-4.63%
|
$73,696
$28.7 P/Share
|
|
Jan 13
2025
|
Jeffrey Eisele Chief Development Officer |
SELL
Open market or private sale
|
Direct |
264
-0.46%
|
$7,392
$28.7 P/Share
|
|
Jan 13
2025
|
Cedric Francois Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
6,247
-1.99%
|
$174,916
$28.7 P/Share
|
|
Jan 13
2025
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
1,599
-2.65%
|
$44,772
$28.7 P/Share
|
|
Jan 13
2025
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,288
-0.2%
|
$64,064
$28.7 P/Share
|
|
Jan 13
2025
|
James George Chopas VP/Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
783
-2.05%
|
$21,924
$28.7 P/Share
|
|
Jan 08
2025
|
Keli Walbert Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,090
+50.0%
|
-
|
|
Jan 06
2025
|
Caroline Baumal Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,816
-4.82%
|
$92,928
$33.81 P/Share
|